KR20240147981A - 항-알파시누클레인 치료 백신 - Google Patents

항-알파시누클레인 치료 백신 Download PDF

Info

Publication number
KR20240147981A
KR20240147981A KR1020247025028A KR20247025028A KR20240147981A KR 20240147981 A KR20240147981 A KR 20240147981A KR 1020247025028 A KR1020247025028 A KR 1020247025028A KR 20247025028 A KR20247025028 A KR 20247025028A KR 20240147981 A KR20240147981 A KR 20240147981A
Authority
KR
South Korea
Prior art keywords
seq
liposome
vaccine composition
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025028A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 파이퍼
맥심 에어
Original Assignee
에이씨 이뮨 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스에이 filed Critical 에이씨 이뮨 에스에이
Publication of KR20240147981A publication Critical patent/KR20240147981A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020247025028A 2022-02-09 2023-02-09 항-알파시누클레인 치료 백신 Pending KR20240147981A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156006.3 2022-02-09
EP22156007 2022-02-09
EP22156007.1 2022-02-09
EP22156006 2022-02-09
PCT/EP2023/053259 WO2023152260A1 (en) 2022-02-09 2023-02-09 Anti-alpha-synuclein therapeutic vaccines

Publications (1)

Publication Number Publication Date
KR20240147981A true KR20240147981A (ko) 2024-10-10

Family

ID=85175955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025028A Pending KR20240147981A (ko) 2022-02-09 2023-02-09 항-알파시누클레인 치료 백신

Country Status (11)

Country Link
US (1) US20250152684A1 (https=)
EP (1) EP4475878A1 (https=)
JP (1) JP2025506472A (https=)
KR (1) KR20240147981A (https=)
AU (1) AU2023219059A1 (https=)
CA (1) CA3248093A1 (https=)
CL (1) CL2024002370A1 (https=)
CR (1) CR20240371A (https=)
IL (1) IL314865A (https=)
MX (1) MX2024009485A (https=)
WO (1) WO2023152260A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024211543A1 (en) * 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
US12156912B2 (en) * 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CN111787942B (zh) * 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
AU2019253193B2 (en) * 2018-04-10 2026-02-05 Ac Immune Sa Anti-abeta therapeutic vaccines
CA3185563A1 (en) * 2020-08-04 2022-02-10 Dorian WINTER Immunogenic compounds

Also Published As

Publication number Publication date
WO2023152260A1 (en) 2023-08-17
CR20240371A (es) 2024-10-16
AU2023219059A1 (en) 2024-07-25
JP2025506472A (ja) 2025-03-11
MX2024009485A (es) 2024-08-14
CA3248093A1 (en) 2023-08-17
US20250152684A1 (en) 2025-05-15
CL2024002370A1 (es) 2024-12-27
IL314865A (en) 2024-10-01
EP4475878A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US20250326806A1 (en) Compositions of Phosphorylated Tau Peptides and Uses Thereof
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
US20230257433A1 (en) Heterologous Administration of Tau Vaccines
KR102869640B1 (ko) 항-aveta 치료적 백신
KR20240147981A (ko) 항-알파시누클레인 치료 백신
TW202221017A (zh) 治療阿茲海默氏症之多表位疫苗
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
JP2023536497A (ja) 免疫原性化合物
TW202221022A (zh) 用於治療阿茲海默症之ｔａｕ疫苗
JP2026505017A (ja) タウ及びアミロイドベータペプチド免疫原組成物及び関連方法
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40087814A (zh) 免疫原性化合物
EA048154B1 (ru) Иммуногенные соединения
KR20250040007A (ko) Tau 펩타이드 면역원 작제물
CN120583938A (zh) 脂质体构建体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000